Affinia Therapeutics develops adeno-associated virus (AAV) gene therapies using its proprietary Affinia Rationally-designed Therapies (ART) platform, which employs AI and structural modeling to enhance targeting and efficacy. The company focuses on providing transformative treatments for patients with severe diseases affecting the heart and nervous system.
Funding
$178.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ECFCFounders
Product
Problem
Many severe diseases affecting the heart and nervous system lack effective treatments, leaving patients with limited options. Traditional gene therapy approaches may suffer from off-target effects and suboptimal efficacy due to inefficient delivery and targeting of therapeutic genes.
Solution
Affinia Therapeutics is developing a new generation of adeno-associated virus (AAV) gene therapies for severe diseases, focusing on the heart and nervous system. Their proprietary Affinia Rationally-designed Therapies (ART) platform uses AI and structural modeling to design AAV vectors with improved tissue targeting and therapeutic efficacy. By rationally designing gene therapies, Affinia aims to create transformative medicines with enhanced safety and effectiveness, addressing the limitations of conventional gene therapy approaches.
Target Audience
The primary target audience consists of patients suffering from severe diseases of the heart and nervous system, as well as the medical professionals who treat them.
Features
- ART platform employing AI and structural modeling for rational AAV vector design
- Enhanced tissue-specific targeting to minimize off-target effects
- Improved therapeutic efficacy through optimized vector design
- Focus on severe diseases affecting the heart and nervous system
- Pipeline of next-generation gene therapies